Table 4.

Univariate analysis and multivariate analysis for candidate risk factors for oxaliplatin hypersensitivity [N=245]

	Univariate analysi s				Multivariate analysis
Factors	B	Adjusted OR	95%CI	p-value	B	Adjusted OR	95%CI	p-value
Age	0.005	1.005	0.982-1.028	0.675
Gender, male	0.663	1.941	1.132-3.326	0.016*	0.966	2.628	1.450-4.763	0.001
Metastasis, yes	-0.034	0.712	0.424-1.196	0.199
Prior platinum exposure, yes	0.894	2.446	1.238-4.834	0.010*	0.818	2.265	1.079-4.755	0.031
History of drug hypersensitivity, yes	0.460	1.584	0.69-3.637	0.278
Neutrophil count (cell/mm3)	0.0002	0.99998	0.9998-1.0002	0.826
Total lymphocyte count (cell/mm3)	0.0004	0.9996	0.9992-0.9999	0.037*
Monocyte count (cell/mm3)	-0.001	0.999	0.998-1.000	0.197	-0.002	0.998	0.996-0.999	0.007
Eosinophil count (cell/mm3)	0.002	1.002	1.000-1.004	0.020*	0.003	1.003	1.001-1.005	0.004
Serum albumin (g/dL)	-0.787	0.455	0.258-0.804	0.007*	-1.111	0.329	0.170-0.638	0.001
Serum creatinine (mg/dL)	1.128	3.090	0.984-9.707	0.053
Oxaliplatin infusion number (times)	0.028	1.028	0.929-1.138	0.589
Total dose of oxaliplatin (mg)	0.0003	1.000	1.000-1.001	0.234
Constant					3.419

^*p < 0.05